Enrique González-Billalabeitia

6PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisPredictive and prognostic markersMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.

Javier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge

|Jan 27, 2026
SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients.

Enrique Gallardo, Alfonso Gómez-de-Iturriaga, Jesús Muñoz-Rodríguez

|Oct 02, 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).

Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura

|Dec 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.

María P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa

|Mar 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.

Jörg Beyer, Laurence Collette, Nicolas Sauvé

|Nov 13, 2019
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).

Ben Tran, Jose M Ruiz-Morales, Enrique Gonzalez-Billalabeitia

Pageof 1

Frequent Collaborators

2 joint publications

Laura Hernández-Vargas

2 joint publications

Claudia Valverde

2 joint publications

Javier Fernandez-Jara

2 joint publications

Nadia Hindi